The company had a dispiriting update to offer about an investigational drug. For the second trading session in less than a week, Roche Holding (RHHBY -6.02%) stock really took it on the chin Wednesday. Dispiriting news about its investigational obesity drug was the culprit; disseminating this, investors sold out of the pharmaceutical veteran. At the end of the day's action, Roche had lost almost 6% of its value. Obesity drug disappoints In a meeting of the European Association for the Study of Diabetes that ...

10'000 Hours/DigitalVision via Getty Images Investment Overview I last covered the Swiss pharma giant Roche (OTCQX:RHHBY) in a note for Seeking Alpha in mid-May, giving the company's stock a "Buy" recommendation. Shares have risen in value by ~22% since, trading at ~$40 at the time of writing, which translates to a market cap valuation of $254bn. In that note I wrote: Roche has been struggling for top and bottom line growth over the past several years, and this may have affected its share price and valuatio ...

Lunit's AI-powered biomarker, Lunit SCOPE PD-L1 TPS, integrates into Roche's navify® Digital Pathology platform to enhance precision medicine and improve cancer biomarker testing SEOUL, South Korea, Sept. 9, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AIpowered solutions for cancer diagnostics and therapeutics, today announced its collaboration with Roche to integrate Lunit SCOPE PD-L1 22C3 TPS into Roche's navify® Digital Pathology platform. This marks the first deployment of Lunit's ...

For Immediate Releases Chicago, IL – September 9, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. (AMZN) , Roche Holding AG (RHHBY) , GE Aerospace (GE) , Canterbury Park Holding Corp. (CPHC) and NVE Corp. (NVEC) . Here are highlights from Monday's Analyst Blog: Top Analyst Reports for Amazon.com, ...

Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, is thrilled to announce a collaboration with Roche, the world's largest biotechnology company and the global leader in invitro diagnostics. In this non-exclusive collaboration, Roche will have the distribution rights to the integrated Stratipath solution, Stratipath Breast. The integration between Stratipath Breast and Roche's navify® Digital Pathology enterprise software enables Roche customers to seamlessly p ...

New Phase II data show vast majority of patients experiencing no relapses or disability progression Fenebrutinib suppressed acute and chronic MRI lesions Fenebrutinib's safety profile was consistent with previous and ongoing clinical trials across multiple diseases including more than 2,700 people to date Basel, 04 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new 48-week data for the investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib from the Phase II FENopta open-labe ...

With the option to self-administer, PiaSky® (crovalimab) has the potential to reduce treatment burden for people with paroxysmal nocturnal haemoglobinuria (PNH) in Europe and their caregivers Approval is based on COMMODORE 2, where subcutaneous (SC) PiaSky once a month was equivalent to intravenous eculizumab every two weeks1,2 PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration3 Basel, 27 August 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announc ...

PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) ("LIXTE" or the "Company"), today announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer Institute (NKI) and supported by F. Hoffmann-La Roche Ltd. ("Roche") for treatment of unresponsive (MSI Low) metastatic colorectal cancer. As part of the clinical trial (NCT06012734, clinicaltrials.gov), LIXTE is providing its lead compound, LB-100, and R ...

Roche Holding AG (RHHBY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices - - has triggered this rating change. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. Since a changing ...

Roche is committed to supporting all those working to overcome the mpox outbreak by providing access to high-quality Polymerase Chain Reaction (PCR) testing Roche confirms that its cobas MPXV test, as well as the LightMix® research use only kits, detect the latest mpox virus variants It is actively working to enhance laboratory testing capacity for mpox worldwide Basel, 20 August 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it is supporting the international response to the mpox global hea ...